Diabetes management has meant the same basic choice for decades: pills, injections, or both. Researchers in Shanghai are working on a third option — a probiotic engineered to sense high blood sugar itself and release a glucose-lowering hormone automatically, with no monitoring or injecting required on the patient’s part.
The research, led by Professor Ye Haifeng at East China Normal University, was published in Nature on August 12. In animal testing, the engineered probiotic performed on par with semaglutide, the drug behind Ozempic and Wegovy.
Key Takeaways
- The probiotic, called GIFT, is engineered to detect rising blood glucose and automatically release GLP-1, the same hormone class that drugs like Ozempic work through.
- In mice with type 1 and type 2 diabetes, it controlled blood sugar about as effectively as semaglutide, without requiring injections or monitoring.
- The team has filed patents and is scaling up production to pharmaceutical manufacturing standards, aiming for a US launch as a health supplement within about two years.
- This is animal research only — it hasn’t been tested in humans yet, and the “supplement” pathway it’s aiming for comes with real regulatory differences from how prescription drugs like Ozempic are approved.
How the Probiotic Actually Works
GIFT is built from a probiotic strain with, according to the researchers, roughly a century of documented safe use, re-engineered using synthetic biology into what the team calls an “intelligent virtual organ.” Taken orally, it temporarily takes up residence in the intestine, where it continuously senses blood glucose levels. When glucose rises, it automatically secretes GLP-1, a hormone that helps the body release insulin and lower blood sugar — the same mechanism that Ozempic and similar drugs use, just delivered by a living organism inside the gut rather than injected. When glucose returns to a normal range, the probiotic stops producing the hormone, creating what the researchers describe as an automatic feedback loop rather than a fixed dose taken on a schedule.
Ye described the approach as an advance specifically because of how it’s built: compared to therapies that rely on transplanting engineered mammalian cells, an oral probiotic sidesteps transplant-related complications and immune reactions. And compared to earlier engineered bacteria that constantly produce GLP-1 regardless of need, GIFT’s on-demand design is intended to offer better stability and safety.
Why the Regulatory Pathway Matters
This is the detail worth paying closest attention to: the team isn’t pursuing GIFT as a prescription drug in the US, at least initially — they’re aiming for it to launch as a health supplement. That distinction carries real consequences. Prescription drugs like Ozempic go through years of large, randomized controlled human trials before the FDA approves them, with strict requirements for proving both safety and effectiveness. Dietary supplements in the US follow a substantially lighter regulatory path: they don’t require FDA approval before hitting shelves, and the specific health claims a company can legally make about them are far more limited than what’s allowed for an approved drug. That’s likely a large part of why a two-year timeline is even plausible — but it also means that, if this becomes available as a supplement, it won’t have gone through the same rigorous, large-scale human testing that Ozempic did before reaching consumers.
What Hasn’t Been Shown Yet
Every result so far comes from mice, not people. Mouse studies frequently don’t translate directly to human outcomes, and there’s no published human trial data yet on GIFT’s safety or effectiveness. The two-year US availability timeline is the research team’s own stated goal, tied to their production scale-up efforts, not a regulatory approval that’s already secured.
Why It’s Still Worth Watching
Diabetes affects more than 530 million adults worldwide, a number projected to exceed 850 million by 2050, and GLP-1 drugs like Ozempic have become so popular that demand has regularly outpaced supply. A shelf-stable, oral, needle-free option — even a supplement-tier one rather than a prescription drug — could meaningfully expand access if it proves out. Whether the science holds up once tested in people, and how regulators and the market ultimately treat a self-dosing living organism sold as a supplement, remain the open questions ahead.
Source: Ye, H. et al. (2026). An engineered oral probiotic for glucose-responsive GLP-1 delivery. Nature, published Aug. 12, 2026; South China Morning Post, “Chinese team aims to put ‘smart’ diabetes probiotic on US shelves within 2 years” (Aug. 17, 2026); China Daily, “Chinese scientists develop new approach for diabetes treatment” (Aug. 14, 2026).